Repurposing an erstwhile cancer drug: A quantitative and therapeutic evaluation of alternative nanosystems for the delivery of colchicine to solid tumors

Journal of Cancer Science and Therapy

Volumn 6, Issue 7, 2014, Pages 236-246

  Tangutoori, Shifalika ^a   Ohta, Akio ^a   Gatley, Samuel ^a   Campbell, Robert B ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Angiogenesis; Cancer; Cationic liposomes; Colchicine; Endothelial cells; Microtubules; PEG; Tumor vasculature; Vascular disrupting agents; tubulin

Indexed keywords

EID: 84906874813     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000277     Document Type: Article

References (54)

1. Siegel R, Ma J, Zou Z, Jemal DVM A (2014) Cancer Statistics, 2014. CA Cancer J Clin 64: 1-9.
2. Griggs J, Hesketh R, Smith GA, Brindle KM, Metcalfe JC, et al. (2001) Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 84: 832-835.
3. Hait WN, Rubin E, Goodin S (2005) Tubulin-targeting agents. Cancer Chemother Biol Response Modif 22: 35-59.
4. Jordan A, Hadfield JA, Lawrence NJ, McGown AT (1998) Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18: 259-296.
5. Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38.
6. Zhou J, Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5: 65-71.
7. Simkin PA (1996) Therapy for gouty individuals. J Rheumatol 23: 1115-1116.
8. Seed L, Slaughter DP, Limarzi LR (1940) Effect of colchicine on human carcinoma. Surgery 7: 696-709.
9. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, et al. (2005) Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. J Surg Res 125: 104-108.
10. Lin ZY, Wu CC, Chuang YH, Chuang WL (2013) Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci 93: 323-328.
11. Tortorici MA, Skledar S, Barnes B, Wasko MC (2004) Promoting the safe use of intravenous colchicine. Am J Health Syst Pharm 61: 2496-2501.
12. McKeown NJ, Horowitz BZ, Garlich F, Young CR, Robertson WO (2007) Deaths from intravenous colchicine resulting from a compounding pharmacy error-Oregon and Washington, 2007. Jama-Journal of the American Medical Association 298: 2364-2366.
13. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, et al. (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 48: 407-414.
14. Deveaux M, Hubert N, Demarly C (2004) Colchicine poisoning: case report of two suicides. Forensic Sci Int 143: 219-222.
15. Folpini A, Furfori P (1995) Colchicine toxicity--clinical features and treatment. Massive overdose case report. J Toxicol Clin Toxicol 33: 71-77.
16. Gendron Y, Bronstein JA, Gras C, Boz P (1989) [Neuromuscular toxicity of colchicine. A case]. Presse Med 18: 1256.
17. Kubler PA (2000) Fatal colchicine toxicity. Med J Aust 172: 498-499.
18. Fernández S, Castro P, Nogué S, Nicolás JM1 (2013) [Refractary shock and severe leukopenia with multisystemic organ failure due to colchicine intentional overdose.] Med Clin (Barc).
19. Bhattacharyya B, Panda D, Gupta S, Banerjee M (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28: 155-183.
20. Yue QX, Liu X, Guo DA (2010) Microtubule-binding natural products for cancer therapy. Planta Med 76: 1037-1043.
21. Crielaard BJ, van der Wal S, Le HT, Bode AT, Lammers T, et al. (2012) Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci 45: 429-435.
22. Staropoli N, Ciliberto D, Botta C1, Fiorillo L, Grimaldi A, et al. (2014) Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials. Cancer Biol Ther 15: 707-720.
23. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, et al. (1998) Cationic Liposomes Target Angiogenic Endothelial Cells in Tumors and Chronic Inflammation in Mice. J Clin Invest 101: 1401-1413.
24. Kalra AV, RB Campbell (2006) Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm Res 23: 2809-2817.
25. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, et al. (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62: 6831-6836.
26. Szoka F Jr, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9: 467-508.
27. Dandamudi S, Campbell RB (2007) The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28: 4673-4683.
28. Dabbas SKR, Dandamudi S, Kuesters G, Campbell R (2008) Importance of the Liposomal Cationic Lipid Content and Type in Tumor Vascular Targeting: Physicochemical Characterization and In Vitro Studies Using Human Primary and Transformed Endothelial Cells. Endothelium 15: 189-204.
29. Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, et al. (2000) Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol 156: 1469-1476.
30. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T (1998) Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 113: 173-182.
31. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99: 683-690.
32. Bouïs D, Hospers GA, Meijer C, Molema G, Mulder NH (2001) Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis 4: 91-102.
33. Barth RJ Jr, Bock SN, Mulé JJ, Rosenberg SA (1990) Unique murine tumorassociated antigens identified by tumor infiltrating lymphocytes. J Immunol 144: 1531-1537.
34. Mukai S, Kjaergaard J, Shu S, Plautz GE (1999) Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 59: 5245-5249.
35. Dandamudi S, Campbell RB (2007) Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta 1768: 427-438
36. BACK A, WALASZEK E, UYEKI E (1951) Distribution of radioactive colchicine in some organs of normal and tumor-bearing mice. Proc Soc Exp Biol Med 77: 667-669.
37. Mehta BM, Rosa E, Fissekis JD, Bading JR, Biedler JL, et al. (1992) In-vivo identification of tumor multidrug resistance with 3H-colchicine [corrected]. J Nucl Med 33: 1373-1377.
38. Dandamudi S, Patil V, Fowle W, Khaw BA, Campbell RB (2009) External magnet improves antitumor effect of vinblastine and the suppression of metastasis. Cancer Sci 100: 1537-1543.
39. Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287: 1302.
40. Campbell RB, Ying B, Kuesters GM, Hemphill R (2009) Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 98: 411-429.
41. Campbell RB (2006) Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem 6: 503-512.
42. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1: 297-315.
43. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, et al. (2009) Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 137: 8-14.
44. Cauda V, Engelke H, Sauer A, Arcizet D, Bräuchle C, et al. (2010) Colchicineloaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett 10: 2484-2492.
45. Betageri GV, Hofmann GA, Banga AK (1999) Enhancement of transdermal iontophoretic delivery of a liposomal formulation of colchicine by electroporation. Drug Delivery 6: 111-115.
46. Das GS, Rao GH, Wilson RF, Chandy T (2000) Colchicine encapsulation within poly(ethylene glycol)-coated poly(lactic acid)/poly(epsilon-caprolactone) microspheres-controlled release studies. Drug Deliv 7: 129-138.
47. Hao Y, Zhao F, Li N, Yang Y, Li K (2002) Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm 244: 73-80.
48. Singh HP, Utreja P, Tiwary AK, Jain S (2009) Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity. AAPS J 11: 54-64.
49. Kulkarni SB, Singh M, Betageri GV (1997) Encapsulation, stability and invitro release characteristics of liposomal formulations of colchicine. J Pharm Pharmacol 49: 491-495.
50. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, et al. (1995) Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 96: 994-1002.
51. Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W, de Vries EG (1999) Visualization of multidrug resistance in vivo. Eur J Nucl Med 26: 283-293.
52. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW (2003) Liposomebased approaches to overcome anticancer drug resistance. Drug Resist Updat 6: 271-279.
53. Mayer LD, Shabbits JA (2001) The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev 20: 87-93.
54. Fanciullino R, Ciccolini J (2009) Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr Med Chem 16: 4361-4371.